Stockscreener 앱 받기
1.41
3.40%
-0.06
전일 마감가:
$1.47
열려 있는:
$1.46
하루 거래량:
1.04M
Relative Volume:
0.41
시가총액:
$143.72M
수익:
$100.56M
순이익/손실:
$-119.05M
주가수익비율:
-1.1463
EPS:
-1.23
순현금흐름:
$-231.16M
1주 성능:
-5.33%
1개월 성능:
-57.23%
6개월 성능:
+9.23%
1년 성능:
-71.71%
1일 변동 폭
$1.39
$1.50
1주일 범위
$1.39
$1.68
52주 변동 폭
$0.87
$6.14
알렉터 Stock (ALEC) Company Profile
명칭
Alector Inc
전화
415-231-5660
주소
131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO
ALEC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALEC
Alector Inc
|
1.42 | 148.78M | 100.56M | -119.05M | -231.16M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.52 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.42 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.79 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.21 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.05 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
알렉터 Stock (ALEC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-22 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-22 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-10-22 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-10-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-07-28 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-12-17 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-12-04 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-11-29 | 재확인 | H.C. Wainwright | Buy |
| 2024-11-26 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-14 | 업그레이드 | Stifel | Hold → Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-09-25 | 개시 | Goldman | Sell |
| 2023-09-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-04-13 | 개시 | Goldman | Sell |
| 2022-03-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-27 | 개시 | William Blair | Outperform |
| 2021-01-15 | 재개 | BofA Securities | Buy |
| 2020-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-04-28 | 개시 | Goldman | Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-19 | 개시 | Stifel | Buy |
| 2019-11-21 | 개시 | BTIG Research | Buy |
| 2019-03-04 | 개시 | Barclays | Overweight |
| 2019-03-04 | 개시 | BofA/Merrill | Buy |
| 2019-03-04 | 개시 | Morgan Stanley | Overweight |
| 2019-03-04 | 개시 | SVB Leerink | Outperform |
모두보기
알렉터 주식(ALEC)의 최신 뉴스
Full technical analysis of Alector Inc. stockTrade Exit Summary & Weekly High Return Forecasts - newser.com
Why Alector Inc. (0Z2) stock attracts wealthy investorsRisk Management & Technical Pattern Based Buy Signals - newser.com
Is Alector Inc. (0Z2) stock supported by strong fundamentalsPortfolio Update Report & Weekly High Conviction Trade Ideas - newser.com
Why Alector Inc. stock remains undervalued2025 Top Gainers & Stepwise Trade Signal Implementation - newser.com
Why Alector Inc. stock remains a top recommendationStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
Is Alector Inc. (0Z2) stock resilient in recession scenariosJuly 2025 Closing Moves & Smart Swing Trading Alerts - newser.com
How to track smart money flows in Alector Inc.2025 Performance Recap & AI Powered Buy/Sell Recommendations - newser.com
Why Alector Inc. (0Z2) stock is a strong buy call2025 Trading Volume Trends & Risk Managed Trade Strategies - newser.com
Volatility clustering patterns for Alector Inc.2025 Market Overview & Breakout Confirmation Alerts - newser.com
Is Alector Inc. stock attractive for growth ETFsCEO Change & Short-Term Trading Opportunity Alerts - newser.com
Will Alector Inc. stock maintain dividend yieldPortfolio Return Summary & Safe Entry Zone Identification - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Alector, Inc. (ALEC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
How Alector Inc. (0Z2) stock compares with market leadersPortfolio Value Report & AI Powered Market Trend Analysis - newser.com
Backtesting results for Alector Inc. trading strategies2025 Institutional Moves & AI Powered Buy and Sell Recommendations - newser.com
Why Alector Inc. stock attracts global investorsJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - newser.com
Alector, Inc. (ALEC) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Alector, Inc. (ALEC) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Alector, Inc. (ALEC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-10-31 | Alector, Inc. (ALEC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALEC | Press Release - Stockhouse
Will Alector Inc. stock attract ESG investors2025 Technical Overview & Accurate Entry and Exit Point Alerts - newser.com
Is Alector Inc. stock a defensive play in 2025Quarterly Growth Report & Verified Trade Idea Suggestions - newser.com
Can Alector Inc. (0Z2) stock hold up in economic slowdown2025 Short Interest & Accurate Technical Buy Alerts - newser.com
Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab - Insider Monkey
How to build a dashboard for Alector Inc. stock2025 Year in Review & Verified Stock Trade Ideas - newser.com
Evaluating Alector Inc. with trendline analysisJuly 2025 Trends & Verified Momentum Watchlists - newser.com
Is Alector Inc a good long term investmentTrend Following Strategies & High Return Trading Portfolio - earlytimes.in
Alector’s Latozinemab Study: A Promising Continuation for Neurodegenerative Disease Treatment - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Alector, Inc. (ALEC) And Encourages Investors to Connect - ACCESS Newswire
10 Best Stocks Under $3 to Invest In - Insider Monkey
Alector’s Phase 3 Trial of Latozinemab Fails to Meet Efficacy Endpoints in FTD-GRN Study - MyChesCo
Alector (ALEC) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
알렉터 (ALEC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.10%
자본화:
|
볼륨(24시간):